KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to $24.8 million.

  • CRISPR Therapeutics AG's Other Non Operating Income fell 1148.09% to $24.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $86.6 million, marking a year-over-year decrease of 1664.49%. This contributed to the annual value of $86.6 million for FY2025, which is 1664.57% down from last year.
  • As of Q4 2025, CRISPR Therapeutics AG's Other Non Operating Income stood at $24.8 million, which was down 1148.09% from $26.2 million recorded in Q3 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Other Non Operating Income peaked at $28.0 million during Q4 2024, and registered a low of $363000.0 during Q1 2022.
  • Its 5-year average for Other Non Operating Income is $14.5 million, with a median of $16.0 million in 2023.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first crashed by 8143.22% in 2022, then soared by 341019.28% in 2023.
  • Over the past 5 years, CRISPR Therapeutics AG's Other Non Operating Income (Quarter) stood at $2.2 million in 2021, then surged by 422.99% to $11.5 million in 2022, then soared by 74.04% to $20.0 million in 2023, then surged by 39.91% to $28.0 million in 2024, then decreased by 11.48% to $24.8 million in 2025.
  • Its last three reported values are $24.8 million in Q4 2025, $26.2 million for Q3 2025, and $22.1 million during Q2 2025.